•Reed Jobs' venture firm, Yosemite, specializing in oncology, is rapidly expanding its efforts to build biotech companies from early academic research.
•Artificial intelligence has become a "huge part" of Yosemite's strategy, significantly accelerating opportunities in drug discovery and clinical trial design.
•Yosemite employs a unique hybrid funding model, blending no-strings-attached philanthropy with traditional venture capital to de-risk novel cancer therapies.
•Reed Jobs' venture firm, Yosemite, specializing in oncology, is rapidly expanding its efforts to build biotech companies from early academic research.
•Artificial intelligence has become a "huge part" of Yosemite's strategy, significantly accelerating opportunities in drug discovery and clinical trial design.
•Yosemite employs a unique hybrid funding model, blending no-strings-attached philanthropy with traditional venture capital to de-risk novel cancer therapies.
